Background: Psoriasis is an immunodysregulatory inflammatory disease associated with comorbidities affecting quality of life. With the advent of new treatments, there is growing need to assess the long-term safety and efficacy of treatments in a real-world setting.
Limitations: Selection and channeling bias can result in potential confounding that needs to be addressed in modeled analyses.
Conclusion: This disease-based registry cohort represents a population exposed to multiple therapies, long disease duration, and multiple comorbidities and can be used to examine comparative safety and efficacy of various therapies. ( J Am Acad Dermatol 2018;78:323-32.)
Key words: biologic therapy; effectiveness; psoriasis; real-world; registry; safety; systemic therapy.
Psoriasis is an immunodysregulatory inflammatory disease with a prevalence of approximately 3% in US adults. 1 Signs and symptoms associated with the skin lesions of psoriasis have a profound impact on physical, psychologic, and social health. 2 A number of serious comorbidities are associated with psoriasis, one of the most common being psoriatic arthritis. The PREPARE study found that 30% of psoriasis patients attending dermatology clinics in Europe and North America had psoriatic arthritis (PsA) when assessed by a rheumatologist. 3 Patients with psoriasis have a higher prevalence of obesity, alcohol use, and smoking compared with age-matched controls. Independent of these risk factors, morbidity and mortality is increased in patients with psoriasis due to a higher prevalence of myocardial infarctions, diabetes, chronic kidney disease, stroke, and metabolic syndrome, particularly when psoriasis is severe. [4] [5] [6] [7] [8] Dermatologists and their psoriasis patients welcome the approval and availability of new treatments, many of which display high efficacy, but the arrival of these medications is also accompanied by questions about long-term safety in the clinical setting. Clinical trials capture safety and efficacy data within the limitation of a restricted population and duration, but are unable to fully characterize long-term safety profiles, particularly regarding malignancies, cardiovascular events, and serious infections. Postmarketing data on medication safety provides important information for patients and their treating physicians to better assess the risk and benefits of therapies and, therefore, allows more informed treatment decisions. Passive reporting systems like the Food and Drug Administration Adverse Event Reporting System have limitations including underreporting and a lack of a comparator group. Registries are an effective mechanism for monitoring safety associated with drug exposure because they efficiently collect detailed information on specific outcomes of interest in a real-world population, which includes patients of various demographics (eg, age, comorbidities, disease severity), who are often excluded from clinical trials. Pharmaceutical companies sponsor phase 4 studies to monitor postmarketing drug safety, and more recent efforts in psoriasis have even included comparator cohorts. 9 However, a need remains for a single unified, observational registry to collect and analyze longitudinal outcomes associated with psoriasis therapies, comorbidities, and the natural course of the disease.
Corrona, a real-world evidence company that operates registries and provides data analytics, developed the Corrona Psoriasis Registry in collaboration with the National Psoriasis Foundation (NPF), a leading patient advocacy organization for people with psoriasis and psoriatic arthritis, to fulfill this need for a real-world, longitudinal, disease-based registry database. The registry, like all Corrona registries, 10 applies a collaborative model using a single protocol and questionnaires.
The objectives of the registry are to study the comparative safety and effectiveness, epidemiology, and treatment patterns of approved systemic psoriasis therapies in a cohort of patients in a real-world setting. This report describes the population, stratified by the therapy use, at registry enrollment.
METHODS

Registry design and study population
The Corrona Psoriasis Registry, an independent prospective, multicenter, observational diseasee based registry, was launched in April 2015, with a target enrollment of [10,000 patients and a minimum follow-up of 8 years. Treating providers may enroll eligible adult patients ($18 years old)
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Clinical trials capture short-term data but do not provide observational, longitudinal outcomes. The Corrona Psoriasis Registry includes a large real-world population receiving biologic therapy for psoriasis. The goal of the registry is to produce real-world safety and efficacy data to guide treatment.
diagnosed with psoriasis by their dermatologist who have initiated an eligible medication at enrollment (incident user) or within the previous 12 months from the date of enrollment (prevalent user). Eligible medications include Food and Drug Administrationeapproved biologics for the treatment of psoriasis (adalimumab, etanercept, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab) and the nonbiologic systemic medications methotrexate, cyclosporine, and apremilast. A limited nonbiologic systemic arm was created for the purpose of an additional comparator cohort, and recruitment goals for this cohort have been met. All treatment decisions are the sole responsibility of the treating practitioner.
In collaboration with its partner, the NPF, as of March 31, 2017, Corrona has recruited a network of 106 private practice and academic dermatology sites across 35 states in the United States, with 188 participating dermatologists (Fig 1) . These numbers are expected to continue to grow as additional sites join the Corrona dermatology network. As of March 31, 2017, the registry had enrolled 2702 patients with approximately 5301 patient visits and 1436 patient-years of follow-up. The Corrona Psoriasis Registry was approved by both local and central (IntegReview, Corrona-PSO-500) review boards at participating sites. Sites are compensated for their effort. All patients provided written, informed consent.
All patients enrolled in the registry through October 1, 2016, were included in this analysis and stratified by therapy use at enrollment: apremilast; other nonbiologic systemic medications (methotrexate, cyclosporine); tumor necrosis factor (TNF) inhibitors (etanercept, adalimumab, infliximab); interleukin (IL) 17A inhibitors (secukinumab, ixekizumab); and the IL-12/23 inhibitor (ustekinumab).
Data collection and assessments
The registry collects data from both patients and their treating dermatologists at the enrollment visit and during routine clinical visits that occur approximately every 6 months (180 days from the last registry visit with a minus 30-day window or $150 days from the last eligible registry visit) through provider and patient questionnaires. Data collected at enrollment include demographics, lifestyle factors, medical history, medication history, clinical assessments, and patient-reported outcomes (PROs). Data collected at each follow-up encounter include adverse events, medication use, health care resource utilization, clinical assessments, laboratory and imaging results, and PROs. Details of serious adverse events and events of special interest are collected along with supporting documents (eg, hospital records, laboratory results) as part of established procedures for collection, validation, and evaluation of a range of safety outcomes associated with psoriasis therapies. Case adjudication of select adverse events is completed by teams of trained, medically qualified reviewers, specific to event type.
Demographics, clinical characteristics, and PROs
The following patient characteristics are collected at both enrollment and follow-up visits: demographics (age, gender, race, ethnicity, weight, body mass index [BMI], insurance, education, work status, and smoking); presence of PsA; disease duration; psoriasis morphology; history of comorbidities (eg, cardiovascular disease, serious infection, cancer, diabetes mellitus, depression/ anxiety); and prior treatment history (biologic and nonbiologic systemics, topical therapies, light and laser therapies). Clinical measures include body surface area (BSA; 0%-100%) affected, worst BSA ever (provider reported from the patient chart and when available), Investigator Global Assessment (IGA; 0-4), and Psoriasis Area and Severity Index (PASI, 0-72). Several PRO measures are collected, including patient-reported pain, itch, and fatigue on a Visual Analog Scale (VAS) of 0 to 100; Work Productivity and Activity Impairment, including all 4 domains (work hours missed or absenteeism, impairment while working or presenteeism, overall percent of work hours affected, daily activities impairment); overall health status measured by Euro-QoL-5 Dimensional (EQ-5D) on a VAS 0-100 (EQ VAS) as well as the 3 level responses for the 5 domains (EQ-5D-3L); and the Dermatology Life Quality Index (DLQI; 0-30).
Abbreviations used:
BSA:
body surface area BMI:
body mass index DLQI:
Dermatology Life Quality Index EQ-5D:
Euro-QoL-5 Dimensional EQ-5D-3L: Euro-QoL-5 Dimensional-3 Level IGA:
Investigator Global Assessment IL: interleukin NPF:
National Psoriasis Foundation PASI:
Psoriasis Area Severity Index PRO:
patient-reported outcome PsA: psoriatic arthritis TNF:
tumor necrosis factor VAS:
visual analog scale J AM ACAD DERMATOL VOLUME 78, NUMBER 2
Statistical analysis
All adult patients enrolled in the Corrona Psoriasis Registry as of October 1, 2016, approximately 18 months since the launch of the registry, who started the eligible therapy at enrollment (incident user) or in the previous 12 months (prevalent user) were included. Descriptive statistics on the overall population and by drug/drug groups were examined. The population was stratified and described by use of the following treatments at registry enrollment: apremilast; other nonbiologic systemic (methotrexate, cyclosporine); TNF inhibitors (etanercept, adalimumab, infliximab); IL-17A inhibitors (secukinumab, ixekizumab); and the sole IL-12/23 inhibitor, ustekinumab (Fig 2) .
Categorical variables (eg, gender, race, BMI, comorbidities) were summarized using frequency counts and percentages. Continuous variables (eg, age, clinical and disease measures) were summarized by the counts and mean (standard deviation). ANOVA and 
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Chi-square tests of association were used to identify if any differences were present among all the therapy groups for the continuous and categorical variables, respectively. Selected significant ANOVA and Chi-square results were subject to post-hoc testing (Bonferroni and Dunn tests for continuous and categorical variables, respectively) to highlight pairwise differences where significant P values are presented in text. All analyses were performed using STATA (StataCorp LP 2015, Stata Statistical Software: Release 14, Version 2, College Station, TX) with significance set at the P = .05 level.
RESULTS
Demographics and patient characteristics
A total of 1942 patients with psoriasis enrolled in the Corrona Psoriasis Registry as of October 1, 2016, including 446 (23%) patients on apremilast, 71 (4%) patients on other nonbiologic systemics, 493 (25%) patients on IL-17A inhibitors, 429 (22%) patients on the IL-12/23 inhibitor, and 503 (26%) patients on TNF inhibitors. Overall mean age for the cohort was 50.3 years, with slightly older patients enrolled in the apremilast (P \ .05) and other nonbiologic systemic groups compared with biologics. Overall, mean BMI was 30.7, with 46% of the patients being obese; differences were seen among the groups, with highest percentage of obese patients in the IL-17A inhibitor group (53%) and lowest in the apremilast group (39%). Differences were also seen in the proportion of patients on private and Medicare/ Medicaid insurance, with patients on apremilast less likely to be on private insurance (P \ .001) and significantly more likely to be on Medicare (P \.001) or Medicaid (P \ .01) when compared with patients in the biologic groups (Table I) .
The mean psoriasis disease duration was 15.6 years, with the highest duration of disease in 221 (11) 66 (15) 14 (20) 67 (14) 34 (8) 40 (8) .0001 Depression, n (%) 375 (19) 74 (17) 18 (25) 100 (20) 87 (20) 96 (19) .35 Anxiety, n (%) 362 (19) 66 (15) 13 (18) 104 (21) 77 (18) 102 (20 the IL-17A inhibitor group (18.9 years, P \.001) and lowest in the other nonbiologic group (10.7 years). Overall, 40% (n = 769) of the patients had a PsA diagnosis (reported by the treating practitioner), with a mean disease duration of 7.8 years.
Groups had comparable history of comorbidities and cardiovascular risk factors; however, fewer patients in the IL-12/23 and TNF inhibitor groups (8% in each group, P \ .005) had a history of cardiovascular disease compared with the other treatment groups (all P \ .005) (Table II) . Slightly less than half of the cohort was biologic-naive (n = 892, 46%), with the highest percentage in the other nonbiologic group (75%) and lowest in the IL-17A inhibitor group (12%, P \.0001).
Disease characteristics
Disease severity in the cohort was assessed through BSA, PASI, and IGA. Mean IGA for the overall cohort at enrollment was 2.2, with almost half (49%) of the patients in the moderate or severe IGA category (Table II with group-wise significance testing). Overall mean BSA was 9.5%, with IL-17 inhibitor patients more likely to have higher BSA (12.3%) at enrollment compared pairwise with the other biologics and patients on apremilast (P \.05). The mean score for worst BSA ever in the overall cohort was 24.2%, with two-thirds of the patients in the moderate or severe BSA category at enrollment, with patients on IL-17 inhibitors having significantly higher worst BSA ever (31.9%, P \ .005) compared pairwise with the other categories. Overall mean PASI score at enrollment was 5.7, with 18% of the patients with PASI [10; at enrollment, a higher proportion of patients on IL-17A inhibitors had PASI [10 (24%, P \ .05) compared pairwise with the other categories (IL-12/23 inhibitor, 19%; TNF inhibitors, 17%; apremilast, 11%; other nonbiologics, 14%) (Table II) . Overall disease severity (as measured by BSA, IGA, and PASI) was higher in the incident users compared with the prevalent users (P \.0001).
Patient-reported outcomes
Detailed PRO measures are presented in Table III . Mean scores for overall patient fatigue and pain were 30.8 and 23.7, respectively, with comparable mean scores across the drug groups (Table III) . About 67% of the cohort were currently employed, with mean overall daily activities impairment of 18.8; all the domains of Work Productivity and Activity Impairment were similar across the drug groups. The mean score for overall health status measured by EQ VAS was 72.8, and the mean score for DLQI was 6.7; almost half of the patients reported moderate, very large, or extremely large effect on life as measured by DLQI.
DISCUSSION
In the absence of psoriasis registries, rheumatology-specific biologic registries historically have provided valuable insights that are indirectly applicable to the treatment of psoriasis, including the association between TNF inhibitors and serious infections, the reduction in cardiovascular event risk with TNF inhibitor treatment, and the outcomes associated with switching from one biologic to another. [10] [11] [12] [13] [14] [15] However, given the large number of (11) 33 (7) 7 (10) 67 (14) 46 (11) 60 (12) \.0001 1: Almost clear 278 (14) 54 (12) 6 (8) 53 (11) 78 (18) 87 (17) (11) 38 (9) 8 (11) 80 (16) 36 (8) 51 (10) BSA, Body surface area; CVD, cardiovascular disease; IGA, Investigator Global Assessment; IL, interleukin; IQR, interquartile range; ns, not significant; PASI, Psoriasis Area and Severity Index; SD, standard deviation; TNF, tumor necrosis factor. *P \ .05. ANOVA and Chi-square tests of association to identify significant difference(s) present among all therapy groups for the continuous and categorical variables, respectively. y Past comorbidities. CVD included revascularization procedures (CABG, stent, angioplasty), ventricular arrhythmia, cardiac arrest, myocardial infarction, acute coronary syndrome, unstable angina, coronary artery disease, congestive heart failure, stroke, transient ischemic attack, hemorrhage with and without hospitalization (serious bleed), deep vein thrombosis, peripheral vascular disease, peripheral arterial disease, pulmonary embolism, and carotid artery disease (hypertension and hyperlipidemia displayed independently).
differences (eg, disease pathophysiology, body weight, age, gender, concomitant medication usage) between psoriasis and rheumatoid arthritis patients, psoriasis-specific clinical assessments and PROs in an observational, longitudinal setting are still needed for dermatologists to make informed treatment decisions. The Corrona Psoriasis Registry was developed in response to this unmet need and will collect many of the data elements that are meaningful to the dermatology community.
Importantly, registries satisfy the need for postapproval safety surveillance. The Corrona Psoriasis Registry data is currently being used to support postapproval safety commitments for the currently approved IL-17einhibitor biologics, secukinumab, ixekizumab, and brodalumab, indicative of the favorable view this type of registry has with regulatory agencies. Corrona will provide information to these agencies upon request. This reflects how the design of postapproval safety studies for biologic therapies has evolved over the last decade from single-arm, open-label clinical trials to registries with multiple comparator cohorts, which help contextualize adverse event incidence rates and provide an enriched research environment for comparative analyses. A large registry, not sponsored by a single pharmaceutical company serves as a central, unbiased repository for longitudinal follow-up data of multiple biologics. Further, enrollment in a single registry facilitates more efficient recruitment of many different types of patients studied at common sites with standardized, in-depth reporting. Long-term follow-up of a well-enrolled population captures not only adverse events but also effects of therapy on disease severity, comorbidities, natural course of disease, and work productivity. Finally, patients switching from one drug to another would contribute data relevant to the incident user pool for new drugs while providing valuable information on drug switching.
Due to broad inclusion criteria, the Corrona Psoriasis Registry population enrolled to date demonstrates differences from clinical trial populations. Notably, the registry's prevalence of psoriatic arthritis (;36%-40%) is higher than that seen in clinical trial populations (;30%). 16, 17 Further, Corrona patients tend to be older, have lower disease severity, and are more likely to have been previously treated with a biologic. These differences are expected given that the registry enrolls both incident and prevalent users (up to 12 months following drug initiation). Because the average drug survival (time to discontinuation) for biologics is \5 years, it is anticipated that baseline data on more incident drug starts will be captured during follow-up visits. 18, 19 Regarding patient age and disease severity, the enrolled Corrona Registry US population is comparable to other international psoriasis registry populations, such as PSOLAR and PsoBest. 9, 20 Currently, the nonbiologic cohort is still relatively large compared with the biologic cohorts, skewing the overall population to look relatively bio-naive.
Admittedly, observational registries have limitations. First, participation by both the treating dermatologists and patients is voluntary, and therefore, selection bias might be introduced. Second, confounding is highly likely. Potential confounders will be examined and considered in future analyses.
Using the Corrona Rheumatoid Arthritis Registry as a prototype, the Corrona Psoriasis Registry expects to contribute meaningful outcomes research on the safety and effectiveness of systemic psoriasis treatments (eg, descriptive studies on patient profile, treatment patterns, association studies, safety studies, comparative effectiveness research). A collaborative model registry provides the opportunity for hypotheses to be generated and evaluated by multiple stakeholders, including the Registry Scientific Advisory Committee, the NPF and its Medical Board, the registry's sponsoring companies, and participating investigators, all of whom may engage in collaborative projects geared toward enriching the psoriasis knowledge base.
